Sirnaomics
Sirnaomics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing targeted therapeutics for significant human diseases using RNA interference (RNAi) technology. Founded in 2007 and headquartered in Gaithersburg, Maryland, with additional offices in Cambridge, Massachusetts, and facilities in Suzhou and Guangzhou, China, Sirnaomics is dedicated to addressing critical medical needs in oncology, anti-fibrotic therapeutics, and viral infections. The company's product portfolio includes several small interfering RNA (siRNA) therapeutics such as STP705 for scar reduction, STP909 for colon cancer, and STP900 for HPV and cervical cancer, among others. Sirnaomics employs proprietary Polypeptide Nano-Particle (PNP) technology to enhance drug delivery, allowing effective targeting of the tumor microenvironment and various cell types, particularly in the liver. Through its innovative approach, Sirnaomics aims to create impactful treatments for diseases with large market opportunities.
4 past transactions
Baisios
Series B in 2023
Baisios is a developer of tumor immune cell therapy technology and is dedicated to the growth of the tumor biotherapy industry.
EDIRNA
Corporate Round in 2023
EDIRNA is an innovative biotech company focused on RNA-Editing technology discovers and develops edit-to cure therapeutics for undruggable target conditions.
RNAimmune
Series A in 2022
RNAimmune, Inc. is a biopharmaceutical company based in Gaithersburg, Maryland, that focuses on developing messenger RNA (mRNA) therapeutics and vaccines. The company employs mRNA as a data carrier to instruct the human body to produce proteins that can combat various diseases, including cancer, infectious diseases, and rare conditions. RNAimmune is a spin-off from Sirnaomics, Inc. and possesses exclusive rights to the proprietary Polypeptide Lipid Nanoparticle (PLNP) technology, which facilitates mRNA delivery. Additionally, the company has created a proprietary artificial intelligence algorithm known as ALEPVA, designed for antigen prediction and vaccine design. By integrating multiple established platform technologies, RNAimmune aims to build a comprehensive mRNA drug discovery and development platform, enhancing its pipeline to address significant unmet medical needs.
RNAimmune
Seed Round in 2021
RNAimmune, Inc. is a biopharmaceutical company based in Gaithersburg, Maryland, that focuses on developing messenger RNA (mRNA) therapeutics and vaccines. The company employs mRNA as a data carrier to instruct the human body to produce proteins that can combat various diseases, including cancer, infectious diseases, and rare conditions. RNAimmune is a spin-off from Sirnaomics, Inc. and possesses exclusive rights to the proprietary Polypeptide Lipid Nanoparticle (PLNP) technology, which facilitates mRNA delivery. Additionally, the company has created a proprietary artificial intelligence algorithm known as ALEPVA, designed for antigen prediction and vaccine design. By integrating multiple established platform technologies, RNAimmune aims to build a comprehensive mRNA drug discovery and development platform, enhancing its pipeline to address significant unmet medical needs.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.